麦肯锡_PharmAsiaSummit2013_Report.pdf

THE PHARMASIA SUMMIT REPORT – CHINA 2013: In Search Of New Growth Models For Big Pharma In China Lead Writers: Gaobo Zhou, Tina Hou, Daniel Liu and Li Ma, McKinsey & Company Editor: Dai Jialing, PharmAsia News, Elsevier Business Intelligence Managing Editor: Tamra Sami, PharmAsia News, Elsevier Business Intelligence Project Manager: Kim Gordon, Elsevier Business Intelligence Design: Gayle Rembold Furbert and Jean Marie Smith, Elsevier Business Intelligence Strategic Oversight: Franck Le Deu, McKinsey & Company; Jimmy Zhang, PhD, MBA, BayHelix; Steve Yang, PhD, BayHelix; Joshua Berlin, Elsevier Business Intelligence For questions ments about this report, please contact: Joshua Berlin, Head of Emerging Markets, Elsevier Business Intelligence, at j.******@. ACKNOWLEDGEMENTS: copyright? 2013 Elsevier Business Intelligence OCTOBER 2013 3 In Search Of New Growth Models For Big Pharma In China INSIDE: Introduction Executive Summary Overview Of Market Trends The Cost Containment Drive The Innovation Imperative Implications And Path Forward For Sustainable Growth Conclusion Appendix I - Glossary Appendix II - PharmAsia Summit Survey Results About Us PharmAsia News Free Trial Offer 7 14 23 31 45 4 5 68 41 40 69 OCTOBER 2013 4 In Search Of New Growth Models For Big Pharma In China China represents an enormous opportunity for the pharmaceutical industry given unmet medical needs, demographic changes (., an aging population, adoption of Western lifestyles) and government support, including China’s health care reform, which has extended basic medical insurance to virtually all of the country’s billion citizens. At the same time, affordability barriers, complicated and lengthy regulatory and reimbursement pathways and a recent drive to pliance present unique challenges to multinational and panies alike. In addition, China is changing. From faster growth in smaller cities to potentially more severe pricing pressure on off-patent medicat